口服强效溴结构域和超末端结构域抑制剂Trotabresib治疗高级别胶质瘤:一项I期「机会窗」研究
本研究为I期机会窗试验,20例复发高级别胶质瘤患者术前接受Trotabresib 30 mg/天第1-4天,术后维持45 mg/天用4天停24天。肿瘤组织与血浆浓度比均值0.84(KPUU 0.37),血和肿瘤组织可见药效标志物调节;维持期最常见3/4级治疗相关不良事件为血小板减少(5/16例),6个月无进展生存率12%。
要点
- Trotabresib可穿透血-脑-肿瘤屏障,在切除肿瘤组织中显示靶点结合。
- 术前用药未导致手术延迟或取消,血浆药代动力学与既往实体瘤数据一致。
- 维持期最常见3/4级治疗相关不良事件为血小板减少(5/16例),6个月无进展生存率12%。
核心结论
- Trotabresib可穿透复发高级别胶质瘤患者的血-脑-肿瘤屏障,并在切除肿瘤组织中显示靶点结合。
- 血浆药代动力学、血药效学和安全性与既往在晚期实体瘤患者中的结果相当。
- 辅助Trotabresib联合替莫唑胺及同步Trotabresib联合替莫唑胺和放疗在新诊断胶质母细胞瘤患者中的研究正在进行(NCT04324840)。
研究设计与样本
- CC-90010-GBM-001(NCT04047303)是一项I期研究,考察Trotabresib在计划接受挽救性切除的复发高级别胶质瘤患者中的药代动力学、药效学和中枢神经系统穿透性。
- 患者术前接受Trotabresib 30 mg/天第1-4天,术后维持Trotabresib 45 mg/天用4天停24天。
- 主要终点为血浆药代动力学和切除组织中的Trotabresib浓度;次要和探索性终点包括安全性、药效学和抗肿瘤活性。
- 20例患者接受术前Trotabresib并接受切除,手术无延迟或取消;16例患者在术后恢复后接受维持Trotabresib。
主要发现
- Trotabresib血浆药代动力学与既往数据一致。
- Trotabresib脑肿瘤组织与血浆浓度比均值为0.84(估计未结合分配系数[KPUU] 0.37),血和脑肿瘤组织中观察到药效标志物调节。
- Trotabresib耐受良好;维持治疗期间最常见的3/4级治疗相关不良事件为血小板减少(5/16例)。
- 6个月无进展生存率为12%。
- 2例患者仍在治疗中,疾病稳定,分别处于第25和第30周期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The bromodomain and extraterminal protein (BET) inhibitor trotabresib has demonstrated antitumor activity in patients with advanced solid tumors, including high-grade gliomas. CC-90010-GBM-001 (NCT04047303) is a phase I study investigating the pharmacokinetics, pharmacodynamics, and CNS penetration of trotabresib in patients with recurrent high-grade gliomas scheduled for salvage resection. METHODS: Patients received trotabresib 30 mg/day on days 1-4 before surgery, followed by maintenance trotabresib 45 mg/day 4 days on/24 days off after surgery. Primary endpoints were plasma pharmacokinetics and trotabresib concentrations in resected tissue. Secondary and exploratory endpoints included safety, pharmacodynamics, and antitumor activity. RESULTS: Twenty patients received preoperative trotabresib and underwent resection with no delays or cancelations of surgery; 16 patients received maintenance trotabresib after recovery from surgery. Trotabresib plasma pharmacokinetics were consistent with previous data. Mean trotabresib brain tumor tissue:plasma ratio was 0.84 (estimated unbound partition coefficient [KPUU] 0.37), and modulation of pharmacodynamic markers was observed in blood and brain tumor tissue. Trotabresib was well tolerated; the most frequent grade 3/4 treatment-related adverse event during maintenance treatment was thrombocytopenia (5/16 patients). Six-month progression-free survival was 12%. Two patients remain on treatment with stable disease at cycles 25 and 30. CONCLUSIONS: Trotabresib penetrates the blood-brain-tumor barrier in patients with recurrent high-grade glioma and demonstrates target engagement in resected tumor tissue. Plasma pharmacokinetics, blood pharmacodynamics, and safety were comparable with previous results for trotabresib in patients with advanced solid tumors. Investigation of adjuvant trotabresib + temozolomide and concomitant trotabresib + temozolomide + radiotherapy in patients with newly diagnosed glioblastoma is ongoing (NCT04324840).
引用
- Moreno V, Manuel Sepúlveda J, Reardon DA, et al. Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study. Neuro Oncol. 2023. PMID: 36455228. doi:10.1093/neuonc/noac263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。